Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610954 | 1.00 | ESR1 (0.60) | ESR1APPSULT1A1ESR2 | |
| SCHEMBL7945789 | 0.90 | ESR1 (0.52) | ESR1ESR2 | |
| SCHEMBL20425286 | 0.87 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL30610951 | 0.87 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL19143729 | 0.81 | ESR1 (0.60) | ESR1APPSULT1A1ESR2 | |
| SCHEMBL7936824 | 0.81 | ESR1 (0.56) | ESR1APPSULT1A1ESR2 | |
| SCHEMBL17845138 | 0.79 | ESR1 (0.58) | ESR1APPSULT1A1 | |
| SCHEMBL31683574 | 0.78 | ESR1 (0.74) | ESR1ESR2 | |
| SCHEMBL15953202 | 0.78 | APP (0.50) | ESR1APP | |
| SCHEMBL31683627 | 0.77 | ESR1 (0.81) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-117551089-A | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-110612297-B | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| CN-110612297-A | Estrogen receptor proteolytic modulators and related methods of use | 阿尔维纳斯运营股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-3573977-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-20180237418-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-08-23 | — | — | US | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
| US-12275716-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
| US-20180237418-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ESR1 15/4885APP 501/4885SULT1A1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.